¼¼°èÀÇ ÇÁ·ÎÅ׿콺 ÁõÈıº ½ÃÀå º¸°í¼­(2025³â)
Proteus Syndrome Global Market Report 2025
»óǰÄÚµå : 1751086
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,156,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,898,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,640,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÇÁ·ÎÅ׿콺 ÁõÈıº ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö ¿¬Æò±Õ 5.0%ÀÇ ¼ºÀå·ü(CAGR)·Î 16¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ Ȱ¿ë È®´ë, ¿ø°ÝÀÇ·á µµÀÔ È®´ë, Èñ±Í Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÇÁ·ÎÅ׿콺 ÁõÈıºÀÇ º¸±Þ·ü Áõ°¡¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ±â¼ú ¹ßÀü, À¯ÀüÀÚ Ä¡·áÀÇ Çõ½Å, AI ±â¹Ý Áø´Ü, ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕ, ¸ÂÃãÇü ÀǾàǰ °³¹ß µîÀÌ ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ µ¹¿¬º¯ÀÌÀÇ ºóµµ Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ÇÁ·ÎÅ׿콺 ÁõÈıº ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯ÀüÀÚ µ¹¿¬º¯ÀÌ´Â À¯Àü Á¤º¸¸¦ º¯È­½ÃŰ´Â DNA ¿°±â¼­¿­ÀÇ ¿µ±¸ÀûÀÎ º¯È­·Î ´Ù¾çÇÑ Áúº´À̳ª ƯÁ¤ ÇüÁúÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯ÀüÀÚ µ¹¿¬º¯ÀÌ Áõ°¡ÀÇ ÁÖ¿ä ¿øÀÎÀº ¹æ»ç¼±, ¿À¿°¹°Áú, È­ÇÐÁ¦Ç°°ú °°Àº µ¹¿¬º¯ÀÌ À¯¹ß ¹°Áú¿¡ ´ëÇÑ È¯°æÀû ³ëÃâÀ̸ç, À̵éÀº DNA ¼Õ»ó°ú À¯ÀüÀÚ º¯È­¸¦ À¯¹ßÇÕ´Ï´Ù. ÇÁ·ÎÅ׿콺 ÁõÈıºÀº AKT1 À¯ÀüÀÚÀÇ Ã¼¼¼Æ÷ µ¹¿¬º¯À̰¡ ¾î¶»°Ô ºñÁ¤»óÀûÀÎ ¼¼Æ÷ Áõ½ÄÀ» À¯¹ßÇÏ´ÂÁö¸¦ ÀÔÁõÇÔÀ¸·Î½á À¯ÀüÀÚ µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ÀÌÇØ¿¡ ±â¿©Çϰí, ¸ðÀÚÀÌÅ©¿Í Áúº´ ÁøÇà¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù ¿µ±¹ º¸°ÇºÎ´Â ¿µ±¹ ³»¿¡¼­ 763°³ÀÇ XE ¿°±â¼­¿­°ú 637°ÇÀÇ »ç·Ê¸¦ º¸°íÇßÀ¸¸ç, XE µ¹¿¬º¯ÀÌ´Â ¿µ±¹ Àü¿ª¿¡ ÆÛÁ® ÀÖÀ¸¸ç, »ç·Ê ¼ö´Â Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ À¯ÀüÀÚ µ¹¿¬º¯ÀÌ ¹ß»ý·üÀÇ Áõ°¡´Â ÇÁ·ÎÅ׿콺 ÁõÈıº ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¿¬±¸ ÀÚ±ÝÀÇ Áõ°¡´Â ÇÁ·ÎÅ׿콺 ÁõÈıº ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¬±¸ ÀÚ±ÝÀº °úÇÐÀû ¹ß°ß, Çõ½Å ¹× ±â¼ú ¹ßÀüÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎ, Á¶Á÷ ¹× ±â°üÀÇ ÀçÁ¤Àû Áö¿øÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Áö¿øÀÇ Áõ°¡´Â ÁÖ·Î ÇÁ·ÎÅ׿콺 ÁõÈıºÀÇ À¯ÀüÀû ¿øÀÎÀ» ´õ ±íÀÌ ÀÌÇØÇϰí, Áø´Ü ¹æ¹ýÀ» °³¼±Çϰí, Ç¥Àû Ä¡·á¹ýÀ» °³¹ßÇØ¾ß ÇÒ Çʿ伺¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ ÁúȯÀº ÷´Ü À¯ÀüÇÐ ¹× Ä¡·áÇÐ ¿¬±¸ÀÇ Á߿伺À» °­Á¶Çϱâ À§ÇØ ¸¹Àº ¿¬±¸ ÀÚ±ÝÀ» ¸ðÀ¸°í ÀÖÀ¸¸ç, ÀÇ·á ±â°ü, Á¤ºÎ ±â°ü ¹× Èñ±Í Áúȯ ´ÜüÀÇ ÅõÀÚ¸¦ À¯µµÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 8¿ù ¿µ±¹ÀÇ »ý¸í°úÇÐ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¾÷°è ´ÜüÀÎ ¹ÙÀÌ¿À»ê¾÷Çùȸ(BioIndustry Association)´Â ¿µ±¹ÀÇ »ý¸í°úÇÐ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ºÎ¹®ÀÌ ¿ÃÇØ ù 2ºÐ±â¿¡ 25¾ï 5,000¸¸ ´Þ·¯ÀÇ ÅõÀÚ¸¦ È®º¸Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. 25¾ï 5õ¸¸ ´Þ·¯ÀÇ ÅõÀÚ¸¦ È®º¸ÇÏ¿© 2023³â¿¡ Á¶´ÞÇÑ 23¾ï 2,000¸¸ ´Þ·¯¸¦ ³Ñ¾î¼¹´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌó·³ ¿¬±¸ ÀÚ±ÝÀÇ Áõ°¡´Â ÇÁ·ÎÅ׿콺 ÁõÈıº ½ÃÀå °³Ã´À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Proteus syndrome is a rare genetic disorder characterized by the abnormal and asymmetric overgrowth of bones, skin, and other tissues. It is caused by a mutation in the AKT1 gene, which triggers uncontrolled cell growth in specific areas of the body. This condition results in a highly variable appearance, with affected individuals displaying disproportionate tissue development. As a progressive disorder, Proteus syndrome worsens over time, often impacting the skeleton, skin, and connective tissues.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types used in the treatment of Proteus syndrome include tablets, capsules, injectables, and other forms. Tablets are a common oral medication form, offering precise dosages for effective treatment. These treatments are administered through oral, parenteral, or other delivery methods and are distributed through both online and offline channels to end users, including hospital pharmacies, retail pharmacies, and specialty clinics.

The proteus syndrome market research report is one of a series of new reports from The Business Research Company that provides proteus syndrome market statistics, including proteus syndrome industry global market size, regional shares, competitors with a proteus syndrome market share, detailed proteus syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the proteus syndrome industry. The Proteus syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proteus syndrome market size has grown strongly in recent years. It will grow from$1.30 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth during the historic period can be attributed to higher diagnosis rates, increased genetic research, greater adoption of precision medicine, expanded government initiatives, and a rise in the demand for genetic testing.

The proteus syndrome market size is expected to see strong growth in the next few years. It will grow to$1.66 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth during the forecast period can be attributed to the increasing focus on personalized medicine, greater use of biomarkers, expanding telemedicine adoption, rising awareness of rare diseases, and the growing prevalence of Proteus syndrome. Key trends expected in the forecast period include technological advancements, innovations in gene therapy, AI-driven diagnostics, integration of big data analytics, and the development of personalized drugs.

The rising frequency of genetic mutations is expected to drive the growth of the Proteus syndrome market in the coming years. Genetic mutations are permanent alterations in DNA sequences that change genetic information, potentially leading to various diseases or unique traits. The increasing prevalence of genetic mutations is mainly due to environmental exposure to mutagens such as radiation, pollutants, and chemicals, which cause DNA damage and genetic changes. Proteus syndrome contributes to the understanding of genetic mutations by demonstrating how a somatic mutation in the AKT1 gene causes abnormal cell growth, offering valuable insights into mosaicism and disease progression. For example, in March 2022, the UK Health Security Agency reported 763 XE sequences and 637 cases in the UK, with XE mutations spreading and case numbers increasing across England. As such, the growing incidence of genetic mutations is fueling the expansion of the Proteus syndrome market.

The rise in research funding is expected to further accelerate the growth of the Proteus syndrome market. Research funding refers to financial support from governments, organizations, or institutions to facilitate scientific discovery, innovation, and technological progress. This increase in funding is primarily driven by the need to better understand the genetic causes of Proteus syndrome, improve diagnostic methods, and develop targeted treatments. The condition attracts significant research funding as it underscores the importance of advanced genetic and therapeutic studies, prompting investments from medical institutions, government bodies, and rare disease organizations. For instance, in August 2024, the BioIndustry Association, a UK-based trade association for life sciences and biotech, reported that the UK's life sciences and biotechnology sector secured $2.55 billion in investments during the first two quarters of the year, surpassing the $2.32 billion raised in 2023. Thus, the growing research funding is driving the development of the Proteus syndrome market.

Leading companies in the Proteus syndrome market are focusing on clinical trials to develop cutting-edge products such as PI3K-a inhibitors to improve treatment efficacy and expand therapeutic options. PI3K-a inhibitors are drugs that target the PI3K-alpha enzyme, which plays a crucial role in regulating cell growth and division. These inhibitors help manage Proteus syndrome by controlling abnormal tissue growth caused by mutations in the PIK3CA gene, which leads to excessive activation of the PI3K/AKT signaling pathway. For example, in November 2024, Risen (Suzhou) Pharma Technology Co., Ltd., a pharmaceutical company based in China, announced that its joint venture had received implicit approval for two clinical trials of its Class 1 new drug, RP903 tablets, under the acceptance numbers CXHL2400566 and CXHL2400565. RP903 is a PI3K-a inhibitor designed to target PIK3CA gene mutations associated with Proteus syndrome (PROS). This achievement underscores the company's commitment to advancing innovative treatments for rare diseases and enhancing the therapeutic options available for PROS patients.

Major players in the proteus syndrome market are Pfizer Inc., Merck Sharp & Dohme Corp, Intas Pharmaceuticals Ltd, Dr Reddy's Laboratories Ltd, Zydus Pharmaceuticals Inc., Biocon Limited, Glenmark Pharmaceuticals Ltd, Curia Global, Concord Biotech Limited, Camber Pharmaceuticals, Chunghwa Chemical Synthesis & Biotech Co Ltd, Farmhispania Group SL, LGM Pharma LLC, ChemWerth Inc, Simson Pharma Limited, Actiza Pharmaceutical, AXXO GmbH, CFM Oskar Tropitzsch GmbH, MedicaPharma, Sumar Biotech LLP, and Kachhela Medex Private Limited.

North America was the largest region in the proteus syndrome market in 2024 and it is expected to be the fastest-growing region in the forecast period. The regions covered in proteus syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the proteus syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proteus syndrome market consists of revenues earned by entities providing services such as diagnostic testing, genetic counseling, specialized treatments, and patient care for managing the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. The proteus syndrome market also includes sales of targeted therapies, pharmaceuticals, medical devices, and diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Proteus Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proteus syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for proteus syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proteus syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Proteus Syndrome Market Characteristics

3. Proteus Syndrome Market Trends And Strategies

4. Proteus Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Proteus Syndrome Growth Analysis And Strategic Analysis Framework

6. Proteus Syndrome Market Segmentation

7. Proteus Syndrome Market Regional And Country Analysis

8. Asia-Pacific Proteus Syndrome Market

9. China Proteus Syndrome Market

10. India Proteus Syndrome Market

11. Japan Proteus Syndrome Market

12. Australia Proteus Syndrome Market

13. Indonesia Proteus Syndrome Market

14. South Korea Proteus Syndrome Market

15. Western Europe Proteus Syndrome Market

16. UK Proteus Syndrome Market

17. Germany Proteus Syndrome Market

18. France Proteus Syndrome Market

19. Italy Proteus Syndrome Market

20. Spain Proteus Syndrome Market

21. Eastern Europe Proteus Syndrome Market

22. Russia Proteus Syndrome Market

23. North America Proteus Syndrome Market

24. USA Proteus Syndrome Market

25. Canada Proteus Syndrome Market

26. South America Proteus Syndrome Market

27. Brazil Proteus Syndrome Market

28. Middle East Proteus Syndrome Market

29. Africa Proteus Syndrome Market

30. Proteus Syndrome Market Competitive Landscape And Company Profiles

31. Proteus Syndrome Market Other Major And Innovative Companies

32. Global Proteus Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Proteus Syndrome Market

34. Recent Developments In The Proteus Syndrome Market

35. Proteus Syndrome Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â